AnorMED US$580 million acquisition by Genzyme Corporation.

Represented AnorMED in its US$580 million acquisition by Genzyme Corporation.

Matter Value: CAD 580,000,000

Represented AnorMED in its US$580 million acquisition by Genzyme Corporation. The transaction was commenced initially as the first ever hostile takeover bid in the history of the North American biotechnology industry, and took the form of an all-cash tender offer in Canada and the United States.

Related Lawyers

Ruby Chan
604.643.6462

Jurisdictions

  • Canada